Clinical Trial Update: Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating safety and efficacy of romiplostim in pediatric idiopathic thrombocytopenic purpura completed; results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura
• Immune Thrombocytopenia

Drugs mentioned

• Romiplostim (Nplate) (romiplostim)

Snippet

Sponsor: Amgen | Conditions: Idiopathic Thrombocytopenic Purpura, Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2011-03-01